Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00698685 · MORE INFO

Limitations, agreements, and source contact

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation · Source last updated 2017-03-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint).
point Of Contact
email
ayeager@azcc.arizona.edu
organization
University of Arizona, Arizona Cancer Center
phone
520-626-0662
title
Andrew M. Yeager, MD
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint).
point Of Contact
email
ayeager@azcc.arizona.edu
organization
University of Arizona, Arizona Cancer Center
phone
520-626-0662
title
Andrew M. Yeager, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice